KENJI NONAKA

M.D., Ph.D.
President, Representative Director and CEO of Orizuru Therapeutics, Inc.

Kenji Nonaka was appointed Representative Director of Orizuru Therapeutics, Inc. in April 2021. He has spent nearly 20 years in research and development for pharmaceutical companies, most recently as Director and General Manager of Research and Development at Janssen Pharmaceutical K.K.. His areas of responsibility in the pharmaceutical industry include malignancies (Blood, prostate cancer), autoimmune diseases, neuropsychiatric disorders (Schizophrenia, Alzheimer's disease), infectious diseases (Hepatitis C, HIV/RSV infection, TB), cardiovascular diseases, and diabetes. Previously, he served as a cardiovascular surgeon in clinical practice for 12 years, including 2 years of artificial heart research in the United States. His industry activities include chairing the PhRMA S&R leadership Forum since 2017.